With summer fully upon us, the UK Investor Magazine presents five equity ideas for August.
Focusing on the UK and US equity markets, we have selected five share tips, each with a compelling investment case. The selection is a mix of growth and value picks spanning a range of industry sectors.
Five stocks for August 2025:
- Greggs (LON: GRG)
- Tekcapital (LON: TEK)
- Filtronic (LON: FTC)
- Adsure Services (AQSE: ADS)
- Tonix Pharmaceuticals (NASDAQ: TNXP)
Greggs
It’s an impossible task trying to pick the bottom in a declining stock. If anyone should achieve such a feat, it’s usually more by luck than judgment. With this in mind, we highlight Greggs shares, not because we’re calling a bottom in the year-long bear run, but because its current valuation is starting to look highly attractive.
Greggs has had a terrible 2025. The baker kicked off the year with a warning on cost inflation and worries about consumer spending. Shares fell from above 2,800p to 2,100p over three days in January.
Then, in early July, Greggs said they believed operating profit for the current year would be lower than the previous year. Shares fell from 1,900p to 1,500p.
The company blamed poor weather and lower footfall.
Nonetheless, the sausage roll specialist is pushing forward with store openings and supply chain improvements, which should be evident in future earnings reports.
Failing any further surprises, the bad news looks to be baked into the Greggs share price cake.
Annualising diluted EPS for the first half of the year puts Greggs on an earnings multiple of around 17x. This is on the expensive side, but looking forward to next year and the impact of new stores and the removal of costs relating to operational improvements, the forward multiple should be a lot lower.
Tekcapital
Tekcapital, one of our ‘Top 20 Picks for 2025’, is approaching a crucial stage in the company’s growth story.
Earlier this year, Tekcapital announced its portfolio company, Guident, had confidentially filed for a NASDAQ IPO and laid the foundations for a Tekcapital share price re-rating.
With a mission to pay out a special dividend once significant gains in portfolio companies have been crystallised, Tekcapital’s business model and value creation centres around building and listing technology companies that improve the lives of a great number of people.
After Microsalt and GenIP floated in 2024, Guident is set to be the next portfolio company from the Tekcapital stable to list, likely at a higher valuation than currently accounted for on Tekcapital’s balance sheet.
A recently released investor report underscored the deep value in Tekcapital’s shares. According to the Tekcapital report, Tekcapital shares were trading at a 64% discount to the company’s NAV as of 30th June. What makes the company a particularly compelling opportunity is that Guident was only valued at $25 million at this point, far less than it could be valued at when it lists in the US.
Figma’s storming US debut and a 250% one-day rally last week emphasise the health of the US primary markets and the interest cutting-edge tech shares can garner.
Filtronic
Filtronic has announced a series of contract wins this year, underscoring the growing demand for the group’s RF, microwave and mmWave communication solutions.
The recent decline in the shares probably represents a slight reality check by the market after the stock surged more than 100% in the first seven months of 2025. We’d argue it brings it closer to the ‘buy zone’.
Filtronic’s sharp ascent so far in 2025 is more than justified. Profits for 2025FY rose to £14m from £3m in the year prior as revenues more than doubled to £56m.
Trading at 22x last year’s earnings, you may feel Filtronic is too richly valued at current levels. But the company’s earnings growth, driven by surging order flow, looks set to continue. If the company continues down its current path, earnings multiples will drop and more than justify its current share price.
Filtronic at 130p per share, would be a steal – if it gets there.
Adsure Services
Aquis-listed Adsure Service is becoming a dividend hero. Implementing a progressive dividend policy since listing in 2023, Adsure’s last dividend puts them on a yield of around 9%.
Dividends are supported by regular and reliable cash flows from long-term contracts for internal audit and business assurance services with government-funded organisations, including housing associations, emergency services, and local councils.
Their half-year report demonstrated another period of growth for the firm, with revenue jumping 19% and EBITDA more than tripling.
Building on its already strong financials, Adsure is laying the groundwork for future margin expansion with the development of its proprietary AI tool, TIAA Insight.
Funded by an Innovate UK grant and trained on decades of real-life client outcomes, TIAA Insight is designed to help improve efficiencies across Adsure’s operating subsidiary, TIAA Ltd, by enhancing human-in-the-loop internal auditors’ workflows.
Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical listed in the US, focused on developing innovative therapies for central nervous system disorders, immunology, and infectious diseases.
This is a high-risk/reward play that may not be every investor’s cup of tea.
The company’s lead asset, TNX-102 SL, is a patented sublingual cyclobenzaprine hydrochloride formulation targeting fibromyalgia management. Fibromyalgia affects an estimated 6-12 million adults in the United States, with current treatment options frequently failing to meet patient and physician expectations. There hasn’t been a new effective non-opioid Fibromyalgia treatment for over 15 years.
Having demonstrated promising results across multiple Phase 3 clinical trials, the company and investors are awaiting a TNX-102 SL FDA decision due in August.
The company has recently launched a Fibromyalgia-focused patient outreach programme, indicating they are fairly confident in the outcome.
With the FDA marketing authorisation decision due by 15th August, Tonix shares could be sharply higher or lower by the end of the month.